Pfizer's Ultra-Long-Acting GLP-1 Achieves Positive Results in Two Phase II Weight Loss Studies
Stock News
Sep 30, 2025
On September 29, Metsera (MTSR.US), which has been acquired by Pfizer (PFE.US), announced positive results from two Phase IIb weight loss studies (VESPER-1 and VESPER-13) for MET-097i. MET-097i is a first-in-class, fully biased, ultra-long-acting GLP-1 receptor agonist (GLP-1-RA) with the potential for once-monthly dosing. Metsera believes that MET-097i can match or exceed the performance of 15mg tirzepatide at steady state and plans to initiate Phase III clinical trials before the end of the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.